Full-Time

Data Sciences Manager

Information and Data Architecture

Posted on 7/4/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's, PhD, Associate's

Category
Data & Analytics (2)
,
Required Skills
LLM
Python
SQL
Confluence
Information Architecture
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree, or a master’s degree with 4–6 years of experience in Product Owner, Platform Owner, or Service Owner roles, or a bachelor’s degree with 6–8 years of experience in those roles, or a diploma with 10–12 years of experience in those roles.
  • Ability to lead and develop high-performing teams.
  • Strong problem-solving, analytical, and critical-thinking skills for complex data challenges.
  • Deep understanding of pharmaceutical industry data, including Process Development, Manufacturing, Engineering Quality, Supply Chain, and Operations.
  • Advanced skills in semantic modeling, Resource Description Framework, Web Ontology Language, Shapes Constraint Language, and ontology development using TopBraid and/or Protégé.
  • Experience creating knowledge graphs with semantic Resource Description Framework technologies such as Stardog and testing models with real data.
  • High proficiency with Resource Description Framework, SPARQL, Connected Data concepts, and triple stores.
  • High proficiency facilitating, capturing, and organizing collaborative discussions using tools such as Lucidchart and Confluence.
  • Expertise in FAIR data principles and their application to healthcare and pharmaceutical data models.
  • Exceptional interpersonal, business analysis, facilitation, and communication skills.
  • Ability to interpret complex regulatory and operational requirements into data models.
  • Analytical thinking for problem-solving in a highly regulated environment.
  • Adaptability to manage and prioritize multiple projects in a dynamic setting.
  • Appreciation for customer- and user-centric product design thinking.
Responsibilities
  • Lead and manage a team of Data Scientists, approximately 4–6 direct reports, providing mentorship, coaching, and performance management.
  • Define team priorities, manage scope, and ensure successful delivery of connected data initiatives aligned with the Operations Data Strategy roadmap.
  • Lead conversations with business stakeholders to elucidate semantic models of pharmaceutical business concepts, definitions, and relationships; negotiate and debate across stakeholders to drive alignment and create system-independent information models.
  • Design, develop, and deploy a connected data ecosystem across Operations using semantic modeling, R2RML, SPARQL, Generative AI, large language models, and GraphRAG.
  • Provide technical leadership in Python-based development, SQL-based data transformation, SPARQL retrieval, and AI system design.
  • Develop comprehensive business information models and ontologies covering CMC, Clinical, and Operations data.
  • Facilitate whiteboarding sessions with business subject matter experts to elicit knowledge, drive interoperability across pharmaceutical domains, and interface between data producers and consumers.
  • Educate and mentor team members and peers on Connected Data and FAIR+ data principles, and champion master-data and reference-data standards.
  • Formalize data models in RDF as OWL and SHACL ontologies that interoperate with relevant healthcare data-exchange standards such as FHIR and IDMP.
  • Build a broad semantic knowledge graph connecting data across end-to-end business processes and enabling data-centric ways of working.
  • Guide development of intelligent systems combining structured and unstructured data, semantic models, and knowledge graphs.
  • Apply pragmatic semantic abstraction to simplify diverse pharmaceutical and healthcare data patterns.
  • Drive adoption of FAIR data principles, data-centric design, and semantic interoperability across solutions.
Desired Qualifications
  • Experience in regulatory data modeling and compliance requirements in the pharmaceutical domain.
  • Familiarity with pharmaceutical lifecycle data, including product development and regulatory submissions.
  • Knowledge of supply chain and operations data modeling in the pharmaceutical industry.
  • Proficiency integrating data from sources such as LIMS, EDC systems, and MES.
  • Hands-on data analysis and data-wrangling experience, including SQL-based data transformation and resolving integration challenges caused by differences in data structure, meaning, or terminology.
  • Expertise in FHIR data standards and their application in healthcare and pharmaceutical data models.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.

INACTIVE